Background: Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. Methods: We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). Results: Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. Conclusion: The data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination. (The TB/COVID-19 Global Study Group)
Tuberculosis and COVID-19 co-infection: description of the global cohort / G.B. Migliori, N. Casco, A.L. Jorge, D.J. Palmero, J.-. Alffenaar, J. Denholm, G.J. Fox, W. Ezz, J.-. Cho, A. Skrahina, V. Solodovnikova, P. Bachez, A. Piubello, M.A. Arbex, T. Alves, M.F. Rabahi, G.R. Pereira, R. Sales, D.R. Silva, M.M. Saffie, R.C. Miranda, V. Cancino, M. Carbonell, C. Cisterna, C. Concha, A. Cruz, N.E. Salinas, M.E. Revillot, J.F. Valdes, I. Fernandez, X. Flores, P.G. Tapia, A. Garavagno, C.G. Vera, M.H. Bahamondes, L.M. Merino, E. Munoz, C. Munoz, I. Navarro, J.N. Subiabre, C. Ortega, S. Palma, A.M. Pradenas, G. Pereira, P.P. Castillo, M. Pinto, R. Pizarro, F.R. Bidegain, P. Rodriguez, C. Sanchez, A.S. Salinas, A. Soto, C. Taiba, M. Venegas, M.S.V. Riquelme, E. Vilca, C. Villalon, E. Yucra, Y. Li, A. Cruz, B. Guelvez, R.V. Plaza, K.Y.T. Hoyos, C. Andrejak, F.-. Blanc, S. Dourmane, A. Froissart, A. Izadifar, F. Riviere, F. Schlemmer, K. Manika, B.D. Diallo, S. Hassane-Harouna, N. Artiles, L.A. Mejia, N. Gupta, P. Ish, G. Mishra, S. Sharma, R. Singla, Z.F. Udwadia, F. Alladio, F. Angeli, A. Calcagno, R. Centis, L.R. Codecasa, L. D'Ambrosio, A. De Lauretis, S. Esposito, B. Formenti, A. Gaviraghi, V. Giacomet, D. Goletti, G. Gualano, A. Matteelli, G.B. Migliori, I. Motta, F. Palmieri, E. Pontali, T. Prestileo, N. Riccardi, L. Saderi, M. Saporiti, G. Sotgiu, C. Stochino, M. Tadolini, A. Torre, S. Villa, D. Visca, E. Danila, S. Diktanas, R.L. Ridaura, F.L.L. Lopez, M.M. Torrico, A. Rendon, O.W. Akkerman, M.B. Souleymane, S. Al-Abri, F. Alyaquobi, K. Althohli, E. Aizpurua, R. Gonzales, J. Jurado, A. Loban, S. Aguirre, R.C. Teixeira, V. De Egea, S. Irala, A. Medina, G. Sequera, N. Sosa, F. Vazquez, F.K. Llanos-Tejada, S. Manga, R. Villanueva-Villegas, D. Araujo, R. Duarte, T.S. Marques, V.I. Grecu, A. Socaci, O. Barkanova, M. Bogorodskaya, S. Borisov, A. Mariandyshev, A. Kaluzhenina, T.A. Vukicevic, M. Stosic, D. Beh, D. Ng, C.W.M. Ong, I. Solovic, K. Dheda, P. Gina, J.A. Caminero, J. Cardoso-Landivar, M.L. De Souza Galvao, A. Dominguez-Castellano, J.-. Garcia-Garcia, I.M. Pinargote, S.Q. Fernandez, A. Sanchez-Montalva, E.T. Huguet, M.Z. Murguiondo, P.-. Bart, J. Mazza-Stalder, F. Bakko, J. Barnacle, A. Brown, S. Chandran, K. Killington, K. Man, P. Papineni, S. Tiberi, N. Utjesanovic, D. Zenner, J.L. Hearn, S. Heysell, L. Young. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 59:3(2022 Mar 01), pp. 2102538.1-2102538.15. [10.1183/13993003.02538-2021]
Tuberculosis and COVID-19 co-infection: description of the global cohort
V. GiacometMembro del Collaboration Group
;S. VillaMembro del Collaboration Group
;
2022
Abstract
Background: Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is still limited. The aim of this study was to describe the features of the TB/COVID-19 co-infected individuals from a prospective, anonymised, multicountry register-based cohort with special focus on the determinants of mortality and other outcomes. Methods: We enrolled all patients of any age with either active TB or previous TB and COVID-19. 172 centres from 34 countries provided individual data on 767 TB-COVID-19 co-infected patients, (>50% population-based). Results: Of 767 patients, 553 (74.0%) out of 747 had TB before COVID-19 (including 234 out of 747 with previous TB), 71 (9.5%) out of 747 had COVID-19 first and 123 (16.5%) out of 747 had both diseases diagnosed within the same week (n=35 (4.6%) on the same day). 85 (11.08%) out of 767 patients died (41 (14.2%) out of 289 in Europe and 44 (9.2%) out of 478 outside Europe; p=0.03): 42 (49.4%) from COVID-19, 31 (36.5%) from COVID-19 and TB, one (1.2%) from TB and 11 from other causes. In the univariate analysis on mortality the following variables reached statistical significance: age, male gender, having more than one comorbidity, diabetes mellitus, cardiovascular disease, chronic respiratory disease, chronic renal disease, presence of key symptoms, invasive ventilation and hospitalisation due to COVID-19. The final multivariable logistic regression model included age, male gender and invasive ventilation as independent contributors to mortality. Conclusion: The data suggest that TB and COVID-19 are a "cursed duet" and need immediate attention. TB should be considered a risk factor for severe COVID disease and patients with TB should be prioritised for COVID-19 preventative efforts, including vaccination. (The TB/COVID-19 Global Study Group)File | Dimensione | Formato | |
---|---|---|---|
2102538.full.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
505.38 kB
Formato
Adobe PDF
|
505.38 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.